Literature DB >> 23532187

Serum albumin is an important prognostic factor for carotid blowout syndrome.

Hsueh-Ju Lu1, Kuo-Wei Chen, Ming-Huang Chen, Pen-Yuan Chu, Shyh-Kuan Tai, Cheng-Hwai Tzeng, Peter Mu-Hsin Chang, Muh-Hwa Yang.   

Abstract

OBJECTIVE: Carotid blowout syndrome is a severe complication of head and neck cancer. High mortality and major neurologic morbidity are associated with carotid blowout syndrome with massive bleeding. Prediction of outcomes for carotid blowout syndrome patients is important for clinicians, especially for patients with the risk of massive bleeding.
METHODS: Between 1 January 2001 and 31 December 2011, 103 patients with carotid blowout syndrome were enrolled in this study. The patients were divided into groups with and without massive bleeding. Prognostic factors were analysed with proportional hazard (Cox) regressions for carotid blowout syndrome-related prognoses. Survival analyses were based on the time from diagnosis of carotid blowout syndrome to massive bleeding and death.
RESULTS: Patients with massive bleeding were more likely to have hypoalbuminemia (albumin <3.5 g/dl; P = 0.023). Univariate analysis of carotid blowout syndrome-related massive bleeding showed that treatment for carotid blowout syndrome (best supportive care, P = 0.000; embolization, P = 0.000), monocytosis (monocytes >1000 cells/μl, P = 0.041) and hypoalbuminemia (P = 0.010) were important to prognosis. Concurrent chemoradiotherapy (P = 0.007), elevated lactate dehydrogenase (>250 U/l; P = 0.050), local recurrence (P = 0.022) and hypoalbuminemia (P = 0.038) were related to poor prognosis in carotid blowout syndrome-related death. In multivariate analysis, best supportive care and hypoalbuminemia were independent factors for both carotid blowout syndrome-related massive bleeding (P = 0.000) and carotid blowout syndrome-related death (P = 0.013), respectively.
CONCLUSION: Best supportive care and serum albumin are important prognostic factors in carotid blowout syndrome. It helps clinicians to evaluate and provide better supportive care for these patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23532187     DOI: 10.1093/jjco/hyt043

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  3 in total

1.  Risk factors for rebleeding and long-term outcomes in patients with head and neck cancer bleeding: a multicenter study.

Authors:  Chih-Kai Wang; Che-Fang Ho; Kuang-Yu Niu; Chia-Chien Wu; Yun-Chen Chang; Chien-Han Hsiao; Chieh-Ching Yen
Journal:  BMC Cancer       Date:  2022-08-02       Impact factor: 4.638

2.  Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer.

Authors:  Katsutoshi Ando; Fumiyuki Takahashi; Motoyasu Kato; Norihiro Kaneko; Tokuhide Doi; Yuichiro Ohe; Fumiaki Koizumi; Kazuto Nishio; Kazuhisa Takahashi
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

3.  Carotid blowout syndrome in patients treated by larynx cancer.

Authors:  Carlos Miguel Chiesa Estomba; Frank Alberto Betances Reinoso; Alejandra Osorio Velasquez; Olalla Castro Macia; Maria Jesus Gonzalez Cortés; Jesus Araujo Nores
Journal:  Braz J Otorhinolaryngol       Date:  2016-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.